Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

672 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advances in multidisciplinary therapy for meningiomas.
Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR; International Consortium on Meningiomas. Brastianos PK, et al. Among authors: wen py. Neuro Oncol. 2019 Jan 14;21(Suppl 1):i18-i31. doi: 10.1093/neuonc/noy136. Neuro Oncol. 2019. PMID: 30649489 Free PMC article. Review.
Brain metastases.
Wen PY, Loeffler JS. Wen PY, et al. Curr Treat Options Oncol. 2000 Dec;1(5):447-58. doi: 10.1007/s11864-000-0072-3. Curr Treat Options Oncol. 2000. PMID: 12057152 Review.
Novel therapies for meningiomas.
Wen PY, Drappatz J. Wen PY, et al. Expert Rev Neurother. 2006 Oct;6(10):1447-64. doi: 10.1586/14737175.6.10.1447. Expert Rev Neurother. 2006. PMID: 17078786 Review.
Targeted drug therapy for meningiomas.
Norden AD, Drappatz J, Wen PY. Norden AD, et al. Among authors: wen py. Neurosurg Focus. 2007;23(4):E12. doi: 10.3171/FOC-07/10/E12. Neurosurg Focus. 2007. PMID: 17961036 Review.
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD; North American Brain Tumor Consortium. Lamborn KR, et al. Among authors: wen py. Neuro Oncol. 2008 Apr;10(2):162-70. doi: 10.1215/15228517-2007-062. Epub 2008 Mar 4. Neuro Oncol. 2008. PMID: 18356283 Free PMC article.
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Wen PY, et al. Neuro Oncol. 2009 Dec;11(6):853-60. doi: 10.1215/15228517-2009-010. Neuro Oncol. 2009. PMID: 19293394 Free PMC article. Clinical Trial.
Advances in meningioma therapy.
Norden AD, Drappatz J, Wen PY. Norden AD, et al. Among authors: wen py. Curr Neurol Neurosci Rep. 2009 May;9(3):231-40. doi: 10.1007/s11910-009-0034-5. Curr Neurol Neurosci Rep. 2009. PMID: 19348712 Review.
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Norden AD, et al. Among authors: wen py. J Neurooncol. 2010 Jan;96(2):211-7. doi: 10.1007/s11060-009-9948-7. Epub 2009 Jun 28. J Neurooncol. 2010. PMID: 19562255 Free PMC article. Clinical Trial.
672 results